Tags

Type your tag names separated by a space and hit enter

Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol.
Schizophr Res. 2002 Oct 01; 57(2-3):227-38.SR

Abstract

Previous clinical trials have clearly shown the superiority of olanzapine to haloperidol in the improvement of extrapyramidal symptoms (EPS) in schizophrenic patients. The primary purpose of this study was to compare EPS profiles in Japanese schizophrenic patients treated with an atypical antipsychotic, olanzapine, or a typical antipsychotic, haloperidol, as measured by the Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS). The DIEPSS, which consists of eight individual parameters and one global assessment (overall severity), was used to evaluate 182 patients enrolled in this 8-week study. The primary safety analysis was maximum change (that could be either a decrease or increase) from baseline in DIEPSS total score. Secondary analyses included change from baseline to maximum in DIEPSS total score, change from baseline to endpoint (LOCF) in DIEPSS total score, and the rank sum of the maximum change (that could be either a decrease or increase) from baseline in the DIEPSS individual items. Incidence of treatment-emergent EPS adverse events using the DIEPSS scale was also analyzed. The olanzapine group showed statistically significant superiority to the haloperidol group on the primary analysis (p<0.001). Secondary analyses also demonstrated olanzapine's superiority in DIEPSS total, parkinsonism, akathisia and overall severity scores (all p< or =0.014). Categorical analysis of treatment-emergent akathisia and parkinsonism syndromes at endpoint showed improvement in the olanzapine group but worsening in the haloperidol group. The results from this study suggest that olanzapine, as in Caucasian populations, is a safe treatment in Japanese patients chronically ill with schizophrenia.

Authors+Show Affiliations

Department of Geriatric Mental Health, National Institute of Mental Health, National Center of Neurology and Psychiatry, Ichikawa, Japan. inada@ncnp-k.go.jpNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12223254

Citation

Inada, Toshiya, et al. "Extrapyramidal Symptom Profiles in Japanese Patients With Schizophrenia Treated With Olanzapine or Haloperidol." Schizophrenia Research, vol. 57, no. 2-3, 2002, pp. 227-38.
Inada T, Yagi G, Miura S. Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol. Schizophr Res. 2002;57(2-3):227-38.
Inada, T., Yagi, G., & Miura, S. (2002). Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol. Schizophrenia Research, 57(2-3), 227-38.
Inada T, Yagi G, Miura S. Extrapyramidal Symptom Profiles in Japanese Patients With Schizophrenia Treated With Olanzapine or Haloperidol. Schizophr Res. 2002 Oct 1;57(2-3):227-38. PubMed PMID: 12223254.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol. AU - Inada,Toshiya, AU - Yagi,Gohei, AU - Miura,Sadanori, PY - 2002/9/12/pubmed PY - 2002/11/26/medline PY - 2002/9/12/entrez SP - 227 EP - 38 JF - Schizophrenia research JO - Schizophr Res VL - 57 IS - 2-3 N2 - Previous clinical trials have clearly shown the superiority of olanzapine to haloperidol in the improvement of extrapyramidal symptoms (EPS) in schizophrenic patients. The primary purpose of this study was to compare EPS profiles in Japanese schizophrenic patients treated with an atypical antipsychotic, olanzapine, or a typical antipsychotic, haloperidol, as measured by the Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS). The DIEPSS, which consists of eight individual parameters and one global assessment (overall severity), was used to evaluate 182 patients enrolled in this 8-week study. The primary safety analysis was maximum change (that could be either a decrease or increase) from baseline in DIEPSS total score. Secondary analyses included change from baseline to maximum in DIEPSS total score, change from baseline to endpoint (LOCF) in DIEPSS total score, and the rank sum of the maximum change (that could be either a decrease or increase) from baseline in the DIEPSS individual items. Incidence of treatment-emergent EPS adverse events using the DIEPSS scale was also analyzed. The olanzapine group showed statistically significant superiority to the haloperidol group on the primary analysis (p<0.001). Secondary analyses also demonstrated olanzapine's superiority in DIEPSS total, parkinsonism, akathisia and overall severity scores (all p< or =0.014). Categorical analysis of treatment-emergent akathisia and parkinsonism syndromes at endpoint showed improvement in the olanzapine group but worsening in the haloperidol group. The results from this study suggest that olanzapine, as in Caucasian populations, is a safe treatment in Japanese patients chronically ill with schizophrenia. SN - 0920-9964 UR - https://www.unboundmedicine.com/medline/citation/12223254/Extrapyramidal_symptom_profiles_in_Japanese_patients_with_schizophrenia_treated_with_olanzapine_or_haloperidol_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0920996401003140 DB - PRIME DP - Unbound Medicine ER -